Erasca Management
Management criteria checks 3/4
Erasca's CEO is Jonathan Lim, appointed in Jul 2018, has a tenure of 6.42 years. total yearly compensation is $5.41M, comprised of 11.5% salary and 88.5% bonuses, including company stock and options. directly owns 11.44% of the company’s shares, worth $84.77M. The average tenure of the management team and the board of directors is 3.6 years and 6.2 years respectively.
Key information
Jonathan Lim
Chief executive officer
US$5.4m
Total compensation
CEO salary percentage | 11.5% |
CEO tenure | 6.4yrs |
CEO ownership | 11.4% |
Management average tenure | 3.6yrs |
Board average tenure | 6.2yrs |
Recent management updates
Recent updates
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Oct 15Erasca: New Focus After Restructuring, But Need More Differentiation
Sep 30Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?
Feb 21We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully
Nov 16Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth
Jun 28We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Jan 20Erasca forms clinical trial partnership with Pfizer for cancer therapy
Oct 20Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Sep 23Erasca adds 10% ahead of R&D Day
Sep 07Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers
Jul 18We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Dec 28CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$159m |
Jun 30 2024 | n/a | n/a | -US$158m |
Mar 31 2024 | n/a | n/a | -US$127m |
Dec 31 2023 | US$5m | US$623k | -US$125m |
Sep 30 2023 | n/a | n/a | -US$231m |
Jun 30 2023 | n/a | n/a | -US$236m |
Mar 31 2023 | n/a | n/a | -US$240m |
Dec 31 2022 | US$8m | US$593k | -US$243m |
Sep 30 2022 | n/a | n/a | -US$138m |
Jun 30 2022 | n/a | n/a | -US$149m |
Mar 31 2022 | n/a | n/a | -US$141m |
Dec 31 2021 | US$850k | US$498k | -US$123m |
Sep 30 2021 | n/a | n/a | -US$154m |
Jun 30 2021 | n/a | n/a | -US$119m |
Mar 31 2021 | n/a | n/a | -US$96m |
Dec 31 2020 | US$2m | US$300k | -US$102m |
Compensation vs Market: Jonathan's total compensation ($USD5.41M) is above average for companies of similar size in the US market ($USD3.22M).
Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.
CEO
Jonathan Lim (52 yo)
6.4yrs
Tenure
US$5,407,446
Compensation
Dr. Jonathan E. Lim, M.D., Co-founded Erasca, Inc. in July 2018 and has been its Executive Chairman since October 2018 and Chief Executive Officer since March 2019. Dr. Lim has also served as a Venture Par...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 6.4yrs | US$5.41m | 11.44% $ 84.8m | |
CFO & Chief Business Officer | 4yrs | US$2.43m | 0.087% $ 646.4k | |
General Counsel & Corporate Secretary | 3.7yrs | US$2.02m | 0.0034% $ 25.5k | |
Chairman of Research & Development | 4.3yrs | US$199.05k | 0% $ 0 | |
Chief Operating Officer | 3.6yrs | no data | no data | |
Chief People Officer | 2.9yrs | no data | no data | |
Senior Vice President of Finance | 3.6yrs | no data | no data | |
Chief Regulatory Affairs Officer | 3.6yrs | no data | no data | |
Senior Vice President of Research | 3.1yrs | no data | no data | |
Chief Medical Officer | 2.6yrs | no data | no data | |
Senior Vice President of Pharmaceutical Development & Operations | 2.1yrs | no data | no data | |
Senior Vice President of Clinical Pharmacology | 1.6yrs | no data | no data |
3.6yrs
Average Tenure
52.5yo
Average Age
Experienced Management: ERAS's management team is considered experienced (3.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 6.2yrs | US$5.41m | 11.44% $ 84.8m | |
Chairman of Research & Development | 4.3yrs | US$199.05k | 0% $ 0 | |
Scientific Advisory Board Member | no data | no data | no data | |
Independent Director | 6.4yrs | US$167.54k | 0.24% $ 1.7m | |
Independent Director | 6.4yrs | US$156.54k | 0.061% $ 452.9k | |
Scientific Advisory Board Member | no data | no data | no data | |
Independent Director | 6.5yrs | US$180.08k | 0.073% $ 543.6k | |
Independent Director | 3.8yrs | US$165.04k | 0.0021% $ 15.7k | |
Scientific Advisory Board Member | no data | no data | no data | |
Independent Director | 5.5yrs | US$165.54k | 0.0078% $ 57.6k | |
Scientific Advisory Board Member | no data | no data | no data | |
Scientific Advisory Board Member | no data | no data | no data |
6.2yrs
Average Tenure
65yo
Average Age
Experienced Board: ERAS's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 08:04 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Erasca, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Alec Stranahan | BofA Global Research |
Naureen Quibria | Capital One Securities, Inc. |
Chris Shibutani | Goldman Sachs |